Welcome to our dedicated page for ORGANON & CO news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & CO stock.
News about Organon & Co. (NYSE: OGN) centers on its activities as a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Company press releases repeatedly describe a portfolio of over 70 products and a mission to deliver impactful medicines and solutions for a healthier every day, with particular emphasis on health needs that uniquely, disproportionately or differently affect women.
Visitors to this news page will find updates on Organon’s product and portfolio developments, including regulatory milestones, commercialization agreements and clinical data presentations. Recent announcements feature US Food and Drug Administration approvals of biosimilars such as BILDYOS and BILPREVDA for all indications of their reference products, and POHERDY as an interchangeable biosimilar to PERJETA for HER2-positive breast cancer. Organon also reports European Commission approvals for BILDYOS and BILPREVDA, expanding access to bone health treatments across the EU.
Organon’s news flow also covers women’s health and dermatology data, such as Phase 3 ADORING program results for VTAMA cream in children with atopic dermatitis, and agreements like the planned divestiture of the JADA System to Laborie and the commercialization of Nilemdo in selected European markets. Financial and corporate governance updates appear through quarterly earnings releases, capital allocation decisions, leadership changes and disclosures related to the Audit Committee investigation into Nexplanon wholesaler sales practices.
For investors, analysts and healthcare observers, the Organon news stream provides insight into how the company manages its women’s health, biosimilars and established brands portfolios, responds to regulatory developments and adjusts its leadership and balance sheet. Regularly reviewing these updates can help readers follow Organon’s evolving product mix, geographic reach and governance actions over time.
Organon (NYSE: OGN) reported Q2 2022 revenues of $1,585 million, a 1% decrease year-over-year but a 5% rise when excluding foreign currency impacts. The company recorded diluted EPS of $0.92 and adjusted EPS of $1.25, which faced a $0.30 negative impact due to acquired IPR&D costs. Adjusted EBITDA was $512 million with a margin of 32.3%. The board declared a quarterly dividend of $0.28 per share. The full-year revenue guidance has been updated to a range of $6.1 billion to $6.3 billion, reflecting ongoing foreign currency challenges.
Organon (NYSE: OGN) announced a research collaboration and exclusive license agreement with Cirqle Biomedical to develop a novel non-hormonal contraceptive. This investigational candidate aims to address the unmet needs of women seeking non-hormonal options. Organon will obtain exclusive rights to develop and commercialize the product, with Cirqle receiving a $10 million upfront payment and potential milestone payments of up to $360 million. The collaboration aligns with Organon’s focus on innovation in women’s health, as highlighted by its commitment to new contraceptive solutions.
Organon (NYSE: OGN) will release its second quarter 2022 financial results on August 4, 2022, prior to a conference call scheduled for 8:30 a.m. EDT. The call will be accessible via webcast on the company's website, and a replay will be available two hours post-event. Organon focuses on women's healthcare with over 60 medicines and products in its portfolio. The company aims to improve women's health through innovation and partnerships in growing international markets.
Cognizant (NASDAQ: CTSH) has entered a multi-year agreement with Organon (NYSE: OGN) to enhance the delivery of healthcare products and improve supply chain management. The partnership involves providing industrial technology support at Organon's manufacturing sites across the UK, Netherlands, Belgium, and Indonesia, utilizing SAP's S4/HANA suite. This collaboration aims to boost manufacturing efficiency, increase medicinal yields, and reduce cycle times, facilitating faster access to vital therapies for women's health.
Organon (NYSE: OGN) has announced a licensing agreement with Shanghai Henlius Biotech for the commercialization of biosimilars referencing Perjeta® (HLX11) and Prolia®/Xgeva® (HLX14). This collaboration reinforces Organon's commitment to expanding its biosimilars portfolio, particularly in women's health, focusing on treatments for breast cancer and osteoporosis. The deal includes a $73 million upfront payment and milestone payments based on achievements. This strategy aligns with Organon's goal to enhance patient access to these critical therapies.
Summary not available.
Organon reported first quarter 2022 revenue of $1,567 million, a 4% increase from the previous year. Net income from continuing operations was $348 million or $1.36 per diluted share, reflecting a 12% decline year-over-year. The company’s adjusted net income was $420 million or $1.65 per diluted share, down 7%. Organon continues to grow its women's health offerings and affirmed its full-year financial guidance. A quarterly dividend of $0.28 was declared, payable on June 16, 2022.
Organon (NYSE: OGN) will release its Q1 2022 financial results on May 5, 2022, before an 8:30 a.m. EDT conference call. The call will be accessible via webcast on the company's website, with a replay available approximately two hours later. Analysts and investors must register in advance using conference ID# 6895016. Formed as a spin-off from Merck (NYSE: MRK), Organon focuses on women's health, boasting a diverse portfolio of over 60 medicines. The company aims to collaborate with biopharmaceutical innovators while maintaining strong cash flows for future growth.
Organon (NYSE: OGN) and Daré Bioscience (NASDAQ: DARE) have entered an agreement for Organon to license global rights to XACIATO, an FDA-approved treatment for bacterial vaginosis (BV) affecting an estimated 21 million U.S. women. The deal includes a $10 million upfront payment to Daré, potential milestone payments of up to $182.5 million, and tiered royalties on net sales. XACIATO is expected to be commercially available in the U.S. in Q4 2022, pending regulatory review. This collaboration aligns with Organon's strategy to enhance women's healthcare options.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022, at 9:10 a.m. EST. A live video webcast of the event will be accessible for investors, analysts, media, and the public. Organon, a global healthcare company formed from a Merck spin-off, focuses on women's health with a diverse portfolio of over 60 products. The company aims to innovate and partner with biopharmaceutical innovators, leveraging its significant global presence.